You are here

Article Text

Article menu

Download PDFPDF

Therapeutics
Oestrogen plus progestogen increased coronary heart disease and breast cancer events in postmenopausal women
Free

https://doi.org/10.1136/ebm.7.5.137

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) JAMA 288, 321; Writing Group for the Women’s Health Initiative Investigators.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial.. Jul 17;. :. –33.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In postmenopausal women, what are the risks and benefits of oestrogen plus progestogen use, particularly with respect to coronary heart disease (CHD) events?

    Design

    Randomised (allocation concealed*), blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee),** placebo controlled trial with a mean 5.2 years of follow up.

    Setting

    40 US clinical centres.

    Participants

    16 608 postmenopausal women who were 50 to 79 years of age (mean age 63.3 y). Exclusion criteria included probable survival of < 3 years, previous breast cancer or other cancer in the past 10 years, and low haematocrit or platelet counts. Follow up was 96.5%.

    Intervention

    Women were allocated to 1 daily tablet of conjugated equine oestrogen, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg (Prempro, Wyeth Ayerst, Philadelphia, PA, USA) …

    View Full Text